Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib-Reference-Cited by-同舟云学术

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Published:2019-05-14 Issue:9 Volume:3 Page:1553-1562
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Awan Farrukh T.¹^ORCID,Schuh Anna²,Brown Jennifer R.³,Furman Richard R.⁴,Pagel John M.⁵,Hillmen Peter⁶^ORCID,Stephens Deborah M.⁷^ORCID,Woyach Jennifer⁸,Bibikova Elena⁹,Charuworn Prista⁹,Frigault Melanie M.⁹¹⁰,Hamdy Ahmed⁹,Izumi Raquel⁹,Linghu Bolan¹¹,Patel Priti⁹,Wang Min Hui⁹,Byrd John C.⁸

Affiliation:

1. Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX;

2. Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;

3. Dana-Farber Cancer Institute, Boston, MA;

4. New York–Presbyterian Hospital, Weill Cornell Medicine, New York, NY;

5. Swedish Cancer Institute, Seattle, WA;

6. St. James’s University Hospital, Leeds, United Kingdom;

7. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;

8. The Ohio State University Comprehensive Cancer Center, Columbus, OH;

9. Acerta Pharma, South San Francisco, CA;

10. Oncology Translational Science, and

11. Oncology Biosciences, IMED Biotech Unit, AstraZeneca, Boston, MA

Abstract

Key PointsAcalabrutinib had good tolerability in patients with relapsed or refractory CLL who were intolerant to ibrutinib. Acalabrutinib demonstrated a high response rate (81%) in patients with relapsed or refractory CLL who were intolerant to ibrutinib.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/9/1553/784544/advances030007.pdf

Reference37 articles.

1. Targeting B cell receptor signalling in cancer: preclinical and clinical advances;Burger;Nat Rev Cancer,2018

2. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician;Byrd;J Clin Oncol,2014

3. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

4. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med,2014

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic Cell Transplantation and Other Cellular Therapies for Chronic Lymphocytic Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

2. Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage;Drugs;2023-12-06

3. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases;Current Topics in Medicinal Chemistry;2023-11

4. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis;Annals of Hematology;2023-10-16

5. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia;JACC: CardioOncology;2023-10